|Over a week ago|
Jana Partners buys TreeHouse Foods, exits Callaway in Q4 » 16:4602/1602/16/21
LH, THS, TGNA, GRA, ELY, BCO, PRSP, EHC, SPY, BLMN, NEWR, CAG
Jana Partners disclosed…
Jana Partners disclosed in an SEC filing its holdings as of December 31, 2020. Jana's four new buys during the fourth quarter included, by size of position, LabCorp (LH), TreeHouse Foods (THS), Tegna (TGNA), and W.R. Grace (GRA). The fund exited three positions during the quarter, including by size of previous position Callaway Golf (ELY) and Brink's Company (BCO). Jana increased its stake in two holdings, including by size of previous position Perspecta (PRSP) and Encompass Health (EHC). The fund decreased its stake in three holdings, including by size of previous position SPDR S&P 500 ETF Trust (SPY), Bloomin' Brands (BLMN), and New Relic (NEWR). Jana's top holdings as of December 31, in order of size, were Conagra (CAG), Perspecta, Encompass Health, LabCorp, and SPDR S&P 500 ETF Trust.
Encompass Health to build 40-bed inpatient rehabilitation hospital in Oklahoma » 07:3002/0802/08/21
Encompass Health and…
Encompass Health and Ascension St. John announced their plans to construct a 40-bed inpatient rehabilitation hospital on East 86th Street North in Owasso, Oklahoma, a northern suburb of Tulsa, Oklahoma. The future hospital is the joint venture's second location. Complementing local acute care services like those provided by Ascension St. John Owasso, the future hospital will offer physical, occupational and speech therapies, and 24-hour nursing care, to restore functional ability and quality of life. The hospital will feature all private patient rooms, a spacious therapy gym with advanced rehabilitation technologies and activities of daily living suite, cafeteria, dining room, pharmacy and therapy courtyard.
|Over a month ago|
Encompass Health activist Jana not 'appeased' by Q4 earnings, The Deal says » 14:4801/2901/29/21
While Encompass Health…
While Encompass Health reported Q4 earnings that beat analyst consensus estimates, the "results and newly issued guidance haven't appeased activist Jana Partners," which previously revealed in November that it held a 1.8% stake in the company, reported The Deal, contacts tell The Fly. "Jana is engaging with the Birmingham, Ala.-based company behind the scenes," The Deal added, according to contacts.
Encompass Health price target lowered to $92 from $97 at Credit Suisse » 08:4301/2801/28/21
Credit Suisse analyst…
Credit Suisse analyst A.J. Rice lowered the firm's price target on Encompass Health to $92 from $97 and keeps an Outperform rating on the shares. The analyst believes the long-term outlook remains intact, with pandemic headwinds viewed as transitory.
Encompass Health price target raised to $87 from $70 at Deutsche Bank » 07:3201/2801/28/21
Deutsche Bank analyst…
Deutsche Bank analyst Pito Chickering raised the firm's price target on Encompass Health to $87 from $70 and keeps a Hold rating on the shares. The shares traded down yesterday as investors remained wary of a softer 2021 EBITDA outlook and a lower base on reinstated long-term guidance, Chickering tells investors in a research note. The analyst, however, believes the long-term growth thesis is intact.
Encompass Health: 'No decision has been made' on home health and hospice unit » 16:2801/2601/26/21
On December 9, 2020, the…
On December 9, 2020, the company announced it is exploring strategic alternatives for its home health and hospice business. The review is ongoing, and no decision has been made. Accordingly, the company's 2021 guidance and longer term growth targets assume the continuation of the current structure of the business. The guidance and growth targets may change depending on the ultimate outcome of the review. Base year 2020 adjusted free cash flow benefited from a temporary payroll tax holiday. Exclusive of this item, the adjusted free cash flow CAGR target would be 8%-10%.
Encompass Health provides 2020-2025 growth targets » 16:2501/2601/26/21
2020-2025 growth targets:…
2020-2025 growth targets: Net operating revenues 8%-10% CAGR; Adjusted EBITDA 8%-10% CAGR; Adjusted free cash flow 5%-7% CAGR.
Encompass Health sees FY21 adjusted EPS $3.31-$3.53, consensus $3.83 » 16:2301/2601/26/21
Sees FY21 revenue…
Sees FY21 revenue $5B-$5.17B, consensus $5.06B. Sees FY21 adjusted EBITDA $925M-$955M.
Encompass Health reports Q4 adjusted EPS 93c, consensus 85c » 16:2101/2601/26/21
Reports Q4 revenue…
Reports Q4 revenue $1.21B, consensus $1.21B.
Encompass Health price target raised to $106 from $85 at UBS » 08:2801/1501/15/21
UBS analyst Whit Mayo…
UBS analyst Whit Mayo raised the firm's price target on Encompass Health to $106 from $85 and keeps a Buy rating on the shares. Late last year, the company announced it would evaluate a range of potential strategic alternatives for its Home Health segment, the analyst tells investors in a research note. Mayo adds that he is "struck" by the "spread" implied at the stock's current levels relative to a potential transaction, noting that Encompass Health shares currently price in only a 78% probability of a deal.